Skip to main content
NCBI home page
Journal of Clinical and Experimental Hepatology logoLink to Journal of Clinical and Experimental Hepatology
. 2011 Nov 9;1(2):94–108. doi: 10.1016/S0973-6883(11)60128-X

Noncirrhotic Portal Hypertension

Harshal Rajekar *, Rakesh K Vasishta **, Yogesh K Chawla †, Radha K Dhiman †,*
PMCID: PMC3940546  PMID: 25755321

Abstract

Portal hypertension is characterized by an increase in portal pressure (> 10 mmHg) and could be a result of cirrhosis of the liver or of noncirrhotic diseases. When portal hypertension occurs in the absence of liver cirrhosis, noncirrhotic portal hypertension (NCPH) must be considered. The prognosis of this disease is much better than that of cirrhosis. Noncirrhotic diseases are the common cause of portal hypertension in developing countries, especially in Asia. NCPH is a heterogeneous group of diseases that is due to intrahepatic or extrahepatic etiologies. In general, the lesions in NCPH are vascular in nature and can be classified based on the site of resistance to blood flow. In most cases, these disorders can be explained by endothelial cell lesions, intimal thickening, thrombotic obliterations, or scarring of the intrahepatic portal or hepatic venous circulation. Many different conditions can determine NCPH through the association of these various lesions in various degrees. Many clinical manifestations of NCPH result from the secondary effects of portal hypertension. Patients with NCPH present with upper gastrointestinal bleeding, splenomegaly, ascites after gastrointestinal bleeding, features of hypersplenism, growth retardation, and jaundice due to portal hypertensive biliopathy. Other sequelae include hyperdynamic circulation, pulmonary complications, and other effects of portosystemic collateral circulation like portosystemic encephalopathy. At present, pharmacologic and endoscopic treatments are the treatments of choice for portal hypertension. The therapy of all disorders causing NCPH involves the reduction of portal pressure by pharmacotherapy or portosystemic shunting, apart from prevention and treatment of complications of portal hypertension.

Keywords: Budd-Chiari syndrome, congenital hepatic fibrosis, extra-hepatic portal venous obstruction, nodular regenerative hyperplasia, noncirrhotic intrahepatic portal hypertension, portal vein thrombosis, portosystemic shunting, schistosomiasis, veno-occlusive disease

Abbreviations: ADPKD, autosomal-dominant polycystic kidney disease; ARPKD, autosomal-recessive polycystic kidney disease; BCS, Budd-Chiari syndrome; CHF, congenital hepatic fibrosis; CTGF, connective tissue growth factor; DSRS, distal splenorenal Shunt; EHPVO, extrahepatic portal vein obstruction; EHPVO, extrahepatic portal vein obstruction; ERCP, endoscopic retrograde cholangio pancreatography; EST, endoscopic sclerotherapy; EVL, endoscopic variceal ligation; FHF, fulminant hepatic failure; GI, Gastrointestinal; GVHD, graft versus cells host disease; HLA, human lymphocyte antigen; HVPG, hepatic vanous pressure gradient; IPH, idiopathic portal hypertension; IVC, inferior vena cava; MRCP, magnetic resonance cholangio pancreatography; NCPF, noncirrhotic portal hypertension; NCPH, noncirrhotic portal hypertension; NRH, nodular regenerative hyperplasia; PVT, portal vein thrombosis; SCT, stem-cell transplantation; TIPS, transjugular intrahepatic portosystemic shunt placement; TIPSS, transjugular intrahepatic portosystemic shunt; VOD, veno-occlusive disease

Full Text

The Full Text of this article is available as a PDF (786.4 KB).

References

  • 1.Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology. 2008;134:1715–1728. doi: 10.1053/j.gastro.2008.03.007. [DOI] [PubMed] [Google Scholar]
  • 2.Banti G. Splenomegalie mit Leberizirrhose. Beitrage zur pathologischen [Splenomegaly with liver cirrhosis. Contribution to pathology] Anat Allgemeinea Pathol. 1889;24:21–33. [Google Scholar]
  • 3.Ravenna P. Banti syndrome (fibrocongestive splenomegaly). Definition, classification and pathogenesis. Arch Intern Med. 1940;66:879–892. [Google Scholar]
  • 4.Mikkelsen WP, Edmondson HA, Peters RL, Redeker AG, Reynolds TB. Extra- and intrahepatic portal hypertension without cirrhosis (hepatoportal sclerosis) Ann Surg. 1965;162:602–620. doi: 10.1097/00000658-196510000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Levison DA, Kingham JG, Dawson AM, Stansfeld AG. Slow cirrhosis or no cirrhosis? A lesion causing benign intrahepatic portal hypertension. J Pathol. 1982;137:253–272. doi: 10.1002/path.1711370309. [DOI] [PubMed] [Google Scholar]
  • 6.Polish E, Christie J, Cohen A, Sullivan B., Jr Idiopathic presinusoidal portal hypertension (Banti's syndrome) Ann Intern Med. 1962;56:624–627. doi: 10.7326/0003-4819-56-4-624. [DOI] [PubMed] [Google Scholar]
  • 7.Boyer JL, Sen Gupta KP, Biswas SK. Idiopathic portal hypertension. Comparison with the portal hypertension of cirrhosis and ex-trahepatic portal vein obstruction. Ann Intern Med. 1967;66:41–68. doi: 10.7326/0003-4819-66-1-41. [DOI] [PubMed] [Google Scholar]
  • 8.Basu AK, Boyer J, Bhattacharya R. Non-cirrhotic portal fibrosis with portal hypertension: a new syndrome. I. Clinical and function studies and result of operations. II. Histopathological studies. Ind J Med Res. 1967;55:336–339. [PubMed] [Google Scholar]
  • 9.Kobayashi Y, Inokuchi K, Saku M. Epidemiology of idiopathic portal hypertension based on a nation-wide survey. Report of the Ministry of Health and Welfare Research Committee on Idiopathic Portal Hypertension. Japan Ministry of Health and Welfare; Tokyo: 1976. pp. 10–15. [Google Scholar]
  • 10.Okuda K, Nakashima T, Okudaira M. Liver pathology of idiopathic portal hypertension. Comparison with NCPF of India. Liver. 1982;2:176–192. doi: 10.1111/j.1600-0676.1982.tb00195.x. [DOI] [PubMed] [Google Scholar]
  • 11.Halllenbeck GA, Adson MA. Esophagogastric varices without hepatic cirrhosis. A clinical study of treatment of their bleeding in 72 cases. Arch Surg. 1961;83:370–383. doi: 10.1001/archsurg.1961.01300150044006. [DOI] [PubMed] [Google Scholar]
  • 12.Sarin SK, Kumar A, Chawla YK. Non-cirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int. 2007;1:398–413. doi: 10.1007/s12072-007-9010-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Sama SK, Bhargawa S, Gopi Nath N. Non-cirrhotic portal fibrosis. Am J Med. 1971;51:160–169. doi: 10.1016/0002-9343(71)90234-8. [DOI] [PubMed] [Google Scholar]
  • 14.Sarin SK. Non-cirrhotic portal fibrosis. Gut. 1989;5:336–351. doi: 10.1136/gut.30.3.406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Okudaira M, Ohbu M, Okuda K. Idiopathic portal hypertension and its pathology. Semin Liver Dis. 2002;22:59–72. doi: 10.1055/s-2002-23207. [DOI] [PubMed] [Google Scholar]
  • 16.Okuda K. Non-cirrhotic portal hypertension versus idiopathic portal hypertension. J Gastroenterol Hepatol. 2002;17(Suppl 3):S204–S213. doi: 10.1046/j.1440-1746.17.s3.2.x. [DOI] [PubMed] [Google Scholar]
  • 17.Kohno K, Ohnishi K, Omata M. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Esche-richia coli in rabbits. Gastroenterology. 1988;94:787–796. doi: 10.1016/0016-5085(88)90255-7. [DOI] [PubMed] [Google Scholar]
  • 18.Sarin SK, Nayyar AK, Malhotra P, Sharma BK, Kumar R, Broor SL. Immunological profile of patients with non-cirrhotic portal fibrosis. J Gastroenterol Hepatol. 1990;5:425–431. doi: 10.1111/j.1440-1746.1990.tb01421.x. [DOI] [PubMed] [Google Scholar]
  • 19.Dash SC, Bhuyan UN, Dinda AK. Increased incidence of glomerulonephritis following spleno-renal shunt surgery in non-cirrhotic portal fibrosis. Kidney Int. 1997;52:482–485. doi: 10.1038/ki.1997.357. [DOI] [PubMed] [Google Scholar]
  • 20.Yamaguchi N, Tokushige K, Haruta I, Yamauchi K, Hayashi N. Analysis of adhesion molecules in patients with idiopathic portal hypertension. J Gastroenterol Hepatol. 1999;14:364–369. doi: 10.1046/j.1440-1746.1999.01857.x. [DOI] [PubMed] [Google Scholar]
  • 21.Yamaguchi E, Yamanoi A, Ono T, Nagasue N. Experimental investigation of the role of endothelin-1 in idiopathic portal hypertension. J Gastroenterol Hepatol. 2007;22:1134–1140. doi: 10.1111/j.1440-1746.2006.04822.x. [DOI] [PubMed] [Google Scholar]
  • 22.Morikawa H, Tamori A, Nishiguchi S. Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension. Mol Med. 2007;13:240–245. doi: 10.2119/2006-00093.Morikawa. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Taneja V, Mehra NK, Sarin SK, Sharma BK, Vaidya MC. Possible HLA influence in governing susceptibility to non-cirrhotic portal fibrosis. Tissue Antigens. 1987;30:184–187. doi: 10.1111/j.1399-0039.1987.tb01618.x. [DOI] [PubMed] [Google Scholar]
  • 24.Nakanuma Y, Nonomura A, Hayashi M. Pathology of the liver in “idiopathic portal hypertension” associated with autoimmune disease. The Ministry of Health and Welfare Disorders of Portal Circulation Research Committee. Acta Pathol Jpn. 1989;39:586–592. [PubMed] [Google Scholar]
  • 25.Abernathy C, Liu YP, Longfellow D. Arsenic: health effects, mechanisms of actions and research issues. Environ Health Perspective. 1999;107:593–597. doi: 10.1289/ehp.99107593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Santra A, Das Gupta JD, De B, Roy B, Guha Mazumder DN. Hepatic manifestations in chronic arsenic toxicity. Ind J Gastroenterol. 1999;18:152–155. [PubMed] [Google Scholar]
  • 27.Huet PM, Guillaume E, Cote J, Legare A, Lavoie P, Viallet A. Noncirrhotic presinusoidal portal hypertension associated with chronic arsenical intoxication. Gastroenterology. 1975;68:1270–1277. [PubMed] [Google Scholar]
  • 28.Das S, Santra A, Lahiri S, Guha Mazumder DN. Implications of oxidative stress and hepatic cytokine (TNF-a and IL-6) response in the pathogenesis of hepatic collagenesis in chronic arsenic toxicity. Toxicol AppI Pharmacol. 2005;204:18–26. doi: 10.1016/j.taap.2004.08.010. [DOI] [PubMed] [Google Scholar]
  • 29.Thomas LB, Popper H, Berk PD, Selikoff I, Falk H. Vinyl-chloride-induced liver disease. From idiopathic portal hypertension (Banti's syndrome) to angiosarcomas. N Engl J Med. 1975;292:17–22. doi: 10.1056/NEJM197501022920104. [DOI] [PubMed] [Google Scholar]
  • 30.Pimentel JC, Menezes AP. Liver disease in vineyard sprayers. Gastroenterology. 1977;72:275–283. [PubMed] [Google Scholar]
  • 31.Cortex Pimentel J, Peixoto Menezes A. Pulmonary and hepatic granulomatous disorders due to the inhalation of cement and mica dusts. Thorax. 1978;33:219–227. doi: 10.1136/thx.33.2.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Podurgiel BJ, McGill DB, Ludwig J, Taylor WF, Muller SA. Liver injury associated with methotrexate therapy for psoriasis. Mayo Clin Proc. 1973;48:787–792. [PubMed] [Google Scholar]
  • 33.Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vit. A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology. 1991;100:1701–1709. doi: 10.1016/0016-5085(91)90672-8. [DOI] [PubMed] [Google Scholar]
  • 34.Barnard JA, Marshall GS, Neblett WW, Gray G, Ghishan FK. Non-cirrhotic portal fibrosis after Wilms' tumor therapy. Gastroenterology. 1986;90:1054–1056. doi: 10.1016/0016-5085(86)90888-7. [DOI] [PubMed] [Google Scholar]
  • 35.Nayak NC. Pathology of non-cirrhotic portal fibrosis in India. In: Okuda K, Omata M, editors. Idiopathic Portal Hypertension. University of Tokyo Press; Tokyo: 1983. pp. 37–47. [Google Scholar]
  • 36.Aikat BK, Bhusnurmath SR, Chuttani PN, Mitra SK, Dutta DV. The pathology of non-cirrhotic portal fibrosis. Hum Pathol. 1979;10:405–418. doi: 10.1016/s0046-8177(79)80046-5. [DOI] [PubMed] [Google Scholar]
  • 37.Tandon BN, Lakshminarayanan R, Bhargava S, Nayak NC, Sama SK. Ultrastructure of the liver in non-cirrhotic portal fibrosis with portal hypertension. Gut. 1970;11:905–910. doi: 10.1136/gut.11.11.905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Kumar A, Bhuyan UN, Nundy S. Glomerulonephritis complicating non-cirrhotic portal fibrosis. J Gastroenterol Hepatol. 1998;13(Suppl 1):271–275. [PubMed] [Google Scholar]
  • 39.Babbs C, Warnes TW, Haboubi NY. Non-cirrhotic portal hypertension with hypoxaemia. Gut. 1998;29:129–131. doi: 10.1136/gut.29.1.129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Matsutani S, Maruyama H, Akiike T. Study of portal vein thrombosis in patients with idiopathic portal hypertension in Japan. Liver Int. 2005;25:978–983. doi: 10.1111/j.1478-3231.2005.01151.x. [DOI] [PubMed] [Google Scholar]
  • 41.Dhiman RK, Chawla Y, Vasishta RK. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol. 2002;17:6–16. doi: 10.1046/j.1440-1746.2002.02596.x. [DOI] [PubMed] [Google Scholar]
  • 42.Bajaj JS, Bhattacharjee J, Sarin SK. Coagulation profile and platelet functions in patients with extrahepatic portal vein obstruction and non-cirrhotic portal fibrosis and influence of hypersplenism. J Gastroenterol Hepatol. 2001;16:641–646. doi: 10.1046/j.1440-1746.2001.02392.x. [DOI] [PubMed] [Google Scholar]
  • 43.Hillaire S, Bonte E, Denninger MH. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut. 2002;51:275–280. doi: 10.1136/gut.51.2.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Ishii M, Katada Y. Idiopathic portal hypertension in a systemic sclerosis patient heterozygous for factor V Leiden mutation. Rheumatol Int. 2003;23:44–46. doi: 10.1007/s00296-002-0259-y. [DOI] [PubMed] [Google Scholar]
  • 45.Bajaj JS, Bhattacharjee J, Sarin SK. Coagulation profile and platelet functions in patients with extrahepatic portal vein obstruction and non-cirrhotic portal fibrosis and influence of hypersplenism. J Gastroenterol Hepatol. 2001;16:641–646. doi: 10.1046/j.1440-1746.2001.02392.x. [DOI] [PubMed] [Google Scholar]
  • 46.Saito K, Nakanuma Y, Takegoshi K. Non-specific immunological abnormalities and association of autoimmune diseases in idiopathic portal hypertension. A study by questionnaire. Hepatogastroenterology. 1993;40:163–166. [PubMed] [Google Scholar]
  • 47.Gürkaynak G, Yildirim B, Aksoy F, Temuçin G. Sonographic findings in noncirrhotic portal fibrosis. J Clin Ultrasound. 1998;26:309–313. doi: 10.1002/(sici)1097-0096(199807/08)26:6<309::aid-jcu5>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  • 48.Sinha R. Grayscale and pulsed Doppler characteristics of non-cirrhotic portal fibrosis: a preliminary report. Clin Radio! 1999;54:156–159. doi: 10.1016/s0009-9260(99)91005-x. [DOI] [PubMed] [Google Scholar]
  • 49.Fukuda K, Kage M, Arakawa M, Nakashima T. Portal vein or hepatic vein? A curious aberrant vasculature in the liver with idiopathic portal hypertension. Acta Pathol Jpn. 1985;35:885–897. [PubMed] [Google Scholar]
  • 50.Dhiman RK, Behera A, Chawla YK, Dilawari JB, Suri S. Portal hypertensive biliopathy. Gut. 2007;56:1001–1008. doi: 10.1136/gut.2006.103606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Chawla Y, Dilawari JB. Anorectal varices and their frequency in cirrhotic and non-cirrhotic portal hypertension. Gut. 1991;32:309–311. doi: 10.1136/gut.32.3.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Sarin SK, Govil A, Jain AK. Prospective randomized trial of endoscopio sclerotherapy versus variceal band ligation for esoph-ageal varices: influence on gastric varices and variceal recurrence. J Hepatol. 1994;26:826–832. doi: 10.1016/s0168-8278(97)80248-6. [DOI] [PubMed] [Google Scholar]
  • 53.Chawla YK, Dilawari JB, Dhiman RK. Sclerotherapy in noncirrhotic portal fibrosis. Dig Dis Sei. 1997;42:1449–1453. doi: 10.1023/a:1018858525312. [DOI] [PubMed] [Google Scholar]
  • 54.Bhargava DK, Dasarathy S, Sundaram KR, Ahuja RK. Efficacy of endoscopio sclerotherapy on long-term management of oesopha-geal varices: a comparative study of results in patients with cirrhosis of the liver, non-cirrhotic portal fibrosis (NCPF) and extrahepatic portal venous obstruction (EHO) J Gastroenterol Hepatol. 1991;6:471–475. doi: 10.1111/j.1440-1746.1991.tb00890.x. [DOI] [PubMed] [Google Scholar]
  • 55.Kochhar R, Goenka MK, Mehta SK. Outcome of injection sclerotherapy using absolute alcohol in patients with cirrhosis, non-cirrhotic portal fibrosis, and extrahepatic portal venous obstruction. Gastrointest Endose. 1991;37:460–464. doi: 10.1016/s0016-5107(91)70780-3. [DOI] [PubMed] [Google Scholar]
  • 56.Kire CF. Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis. Br Med J. 1989;298:1363–1365. doi: 10.1136/bmj.298.6684.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Grace ND, Groszmann RJ, Garcia-Tsao G, Burroughs AK, Pagliaro L, Makuch RW. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology. 1998;28:868–880. doi: 10.1002/hep.510280339. [DOI] [PubMed] [Google Scholar]
  • 58.Sarin SK, Jain AK, Jain M. A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. Am J Gastroenterol. 2002;97:1010–1015. doi: 10.1111/j.1572-0241.2002.05622.x. [DOI] [PubMed] [Google Scholar]
  • 59.Dhiman RK, Chawla Y, Taneja S, Biswas R, Sharma TR, Dilawari JB. Endoscopio sclerotherapy of gastric variceal bleeding with N-butyl-2-cyanoacrylate. J Clin Gastroenterol. 2002;35:222–227. doi: 10.1097/00004836-200209000-00005. [DOI] [PubMed] [Google Scholar]
  • 60.Hirota S, Ichikawa S, Matsumoto S. Interventional radio-logic treatment of idiopathic portal hypertension. Cardiovasc Intervent Radiol. 1999;22:311–314. doi: 10.1007/s002709900394. [DOI] [PubMed] [Google Scholar]
  • 61.Mitra SK, Rao KL, Narasimhan KL. Side-to-side lienorenal shunt without splenectomy in non-cirrhotic portal hypertension in children. J Pediatr Surg. 1993;28:398–401. doi: 10.1016/0022-3468(93)90239-h. [DOI] [PubMed] [Google Scholar]
  • 62.Warren WD, Henderson JM, Millikan WJ. Management of variceal bleeding in patients with noncirrhotic portal vein thrombosis. Ann Surg. 1988;207:623–634. doi: 10.1097/00000658-198805000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. J Gastroenterol Hepatol. 2002;17:526–534. doi: 10.1046/j.1440-1746.2002.02764.x. [DOI] [PubMed] [Google Scholar]
  • 64.Sharma BC, Singh RP, Chawla YK, Narasimhan KL, Rao KL, Mitra SK. Effect of shunt surgery on spleen size, portal pressure and esophageal varices in noncirrhotic portal fibrosis. J Gastroenterol Hepatol. 1997;12:582–584. doi: 10.1111/j.1440-1746.1997.tb00489.x. [DOI] [PubMed] [Google Scholar]
  • 65.Sarin SK, Kumar A. Non-cirrhotic portal hypertension. Clin Liver Dis. 2006;10:627–651. doi: 10.1016/j.cld.2006.08.021. [DOI] [PubMed] [Google Scholar]
  • 66.Sarin SK, Agarwal SR. Extrahepatic portal vein obstruction. Semin Liver Dis. 2002;22:43–58. doi: 10.1055/s-2002-23206. [DOI] [PubMed] [Google Scholar]
  • 67.Tizard JPM. Portal hypertension following exchange transfusion through the umbilical vein. Proc R Soc Med. 1962;55:772–779. doi: 10.1177/003591576205500907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Shaldon S, Sherlock S. Obstruction to the extrahepatic portal system in childhood. Lancet. 1962;1:63–67. doi: 10.1016/s0140-6736(62)91717-8. [DOI] [PubMed] [Google Scholar]
  • 69.Yachha SK, Aggarwal R, Sharma BK. Functional protein C and anticardiolipin antibodies in children with portal vein thrombosis. Ind J Gastro. 2001;20:47–49. [PubMed] [Google Scholar]
  • 70.Primignani M, Martinelli I, Bucciarelli P. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005;41:603–608. doi: 10.1002/hep.20591. [DOI] [PubMed] [Google Scholar]
  • 71.Cardin F, Graffeo M, McCormick PA. Adult “ideopathic” extrahepatic venous thrombosis. Importance of putative “latent” myeloproliferative disorders and comparison with cases with known etiology. Dig Dis Sci. 1992;37:335–339. doi: 10.1007/BF01307724. [DOI] [PubMed] [Google Scholar]
  • 72.Winslow ER, Brunt LM, Drebin JA. Portal vein thrombosis after splenectomy. Am J Surg. 2002;184:631–635. doi: 10.1016/s0002-9610(02)01095-4. [Discussion 635-6.] [DOI] [PubMed] [Google Scholar]
  • 73.Habu D, Nishiguchi S, Shiomi S. Portal vein thrombosis following percutaneous ethanol injection therapy for hepatocellular carcinoma. Ind J Gastroenterol. 2002;21:162–163. [PubMed] [Google Scholar]
  • 74.Matsumoto K, Yamao K, Ohashi K. Acute portal vein thrombosis after EUS-guided FNA of pancreatic cancer: case report. Gastrointest Endosc. 2003;57:269–271. doi: 10.1067/mge.2003.79. [DOI] [PubMed] [Google Scholar]
  • 75.Webb LJ, Sherlock S. The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. Q J Med. 1979;192:627–639. [PubMed] [Google Scholar]
  • 76.Boles ET, Wise WE, Birken G. Extrahepatic portal hypertension in children. Long-term evaluation. Am J Surg. 1986;151:734–739. doi: 10.1016/0002-9610(86)90054-1. [DOI] [PubMed] [Google Scholar]
  • 77.Voigt MD, Trey G, Levitt NS. Autonomic neuropathy in extrahepatic portal vein thrombosis: evidence for impaired autonomic reflex arc. J Hepatol. 1997;26:634–641. doi: 10.1016/s0168-8278(97)80430-8. [DOI] [PubMed] [Google Scholar]
  • 78.Dhiman RK, Puri P, Chawla Y. Biliary changes in extrahepatic portal venous obstruction: compression by collaterals or ischemic? Gastrointest Endosc. 1999;50:646–652. doi: 10.1016/s0016-5107(99)80013-3. [DOI] [PubMed] [Google Scholar]
  • 79.Mehrotra RN, Bhatia V, Dabadghao P. Extrahepatic portal vein obstruction in children: anthropometry, growth hormone, and insulin-like growth factor 1. J Pediatr Gastroenterol Nutr. 1997;25:520–523. doi: 10.1097/00005176-199711000-00006. [DOI] [PubMed] [Google Scholar]
  • 80.Kato T, Romero R, Koutouby R. Portosystemic shunting in children during the era of endoscopic therapy: improved postoperative growth parameters. J Pediatr Gastroenterol Nutr. 2000;30:419–425. doi: 10.1097/00005176-200004000-00013. [DOI] [PubMed] [Google Scholar]
  • 81.Poddar U, Thapa BR, Singh K. Band ligation plus sclerotherapy versus sclerotherapy alone in children with extrahepatic portal venous obstruction. J Clin Gastroenterol. 2005;39:626–629. doi: 10.1097/01.mcg.0000170765.36825.66. [DOI] [PubMed] [Google Scholar]
  • 82.Orloff MJ, Orloff MS, Girard B. Bleeding esophago-gastric varices from extrahepatic portal hypertension. 40 year experience with portal systemic shunt. J Am Coll Surg. 2002;194:717–728. doi: 10.1016/s1072-7515(02)01170-5. [DOI] [PubMed] [Google Scholar]
  • 83.Superina R, Shneider B, Emre S, Sarin S, de Ville de Goyet J. Surgical guidelines for the management of extra-hepatic portal vein obstruction. Pediatr Transplant. 2006;10:908–913. doi: 10.1111/j.1399-3046.2006.00598.x. [DOI] [PubMed] [Google Scholar]
  • 84.Sharma M, Pathak A. Intracholedochal varices in portal hypertensive biliopathy. Eur J Radiol Extra. 2009;72:e119–e123. [Google Scholar]
  • 85.Dhiman RK, Behera A, Chawla YK, Dilawari JB, Suri S. Portal hypertensive biliopathy. Gut. 2007;56:1001–1008. doi: 10.1136/gut.2006.103606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Chawla Y, Duseja A, Dhiman RK. Review article: the modern management of portal vein thrombosis. Aliment Pharmacol Ther. 2009;30:881–894. doi: 10.1111/j.1365-2036.2009.04116.x. [DOI] [PubMed] [Google Scholar]
  • 87.Adel AF Mahmoud. Schistosomiasis and other trematode infections. Harrison's Principles of Internal Medicine 17th ed., 1499-503.
  • 88.Andrade ZA. Schistosomal hepatopathy. Mem Inst Oswaldo Cruz. 2004;99(5 Suppl 1):51–57. doi: 10.1590/s0074-02762004000900009. [DOI] [PubMed] [Google Scholar]
  • 89.Carruthers RH, Sinha P. Bilharzial portal fibrosis: an important cause of portal hypertension. Ann R Coll Surg Engl. 1978;60:49–52. [PMC free article] [PubMed] [Google Scholar]
  • 90.Dessein AJ, Hillaire D, Elwali NE. Severe hepatic fibrosis in Sch/sfosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene. Am J Hum Genet. 1999;65:709–721. doi: 10.1086/302526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Coelho RB. Anatomiapa-tolágica das afeegáes hepáticas. Editora da UFPE, Coelho RB; Recife: 1971. Lesões hepáticas secundarias; pp. 59–77. [Google Scholar]
  • 92.De Cock KM. Hepatosplenic schistosomiasis: a clinical review. Gut. 1986;27:734–745. doi: 10.1136/gut.27.6.734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Stuiver PC. Acute schistosomiasis (Katayama fever) Br Med J. 1984;288:221–222. doi: 10.1136/bmj.288.6412.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Coutinho A. Hemodynamic studies of portal hypertension in schistosomiasis. Am J Med. 1968;4:547–556. doi: 10.1016/0002-9343(68)90055-7. [DOI] [PubMed] [Google Scholar]
  • 95.Andrade ZA, Santana Filho S, Rubim E. Hepatic changes in advanced schistosomiasis. Gasfroenferology. 1962;42:393–400. [PubMed] [Google Scholar]
  • 96.Cheever AW, Andrade ZA. Alterations of the intrahepatic vascu-lature in hepatosplenic schistosomiasis mansoni. Am J Trop Med Hyg. 1971;20:425–432. doi: 10.4269/ajtmh.1971.20.425. [DOI] [PubMed] [Google Scholar]
  • 97.De Cock KM. Splenomegaly and portal hypertension in Nairobi, Kenya: a study in geographical medicine. University of Bristol, MD Thesis, 1983.
  • 98.Jordan P. Diagnostic and laboratory techniques. In: Jordan P, Webbe G, editors. Schistosomiasis. Epidemiology, Treatment and Control. Heinemann; London: 1982. pp. 165–183. [Google Scholar]
  • 99.Smithers SR, Doenhoff MJ. Schistosomiasis. In: Cohen S, Warren KS, editors. Immunology of Parasitic Infections. Blackwell; Oxford: 1982. pp. 527–607. [Google Scholar]
  • 100.Dusek J, Kubasta M, Kodousek R, Kubastova B. Needle biopsy of the liver in schistosomiasis mansoni: the value of histologi-cal examination. J Trop Med Hyg. 1965;68:189–195. [PubMed] [Google Scholar]
  • 101.De Cock KM. Human schistosomiasis and its management. J Infect. 1984;8:5–12. doi: 10.1016/s0163-4453(84)93165-7. [DOI] [PubMed] [Google Scholar]
  • 102.Mutapi F, Ndhlovu PD, Hagan P. Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection. J Infect Dis. 1998;178:289–293. doi: 10.1086/517456. [DOI] [PubMed] [Google Scholar]
  • 103.Siqueira ES, Rohr MR, Libera ED, Castro RR, Ferrari AP. Band ligation or sclerotherapy as endoscopio treatment for oesophageal varices in schistosomotic patients: results of a randomized study. HPB Surg. 1998;11:27–32. doi: 10.1155/1998/68394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.el Tourabi H, el Amin AA, Shaheen M, Woda SA, Homeida M, Harron DW. Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. Ann Trop Med Parasitol. 1994;88:493–500. doi: 10.1080/00034983.1994.11812896. [DOI] [PubMed] [Google Scholar]
  • 105.da Silva LC, Strauss E, Gayotto LC. A randomized trial for the study of the elective surgical treatment of portal hypertension in mansonic schistosomiasis. Ann Surg. 1986;204:148–153. doi: 10.1097/00000658-198608000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Ezzat FA, Abu-Elmagd KM, Aly MA. Selective shunt versus nonshunt surgery for management of both schistosomal and non-schistosomal variceal bleeders. Ann Surg. 1990;212:97–108. doi: 10.1097/00000658-199007000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Shorbagi A, Bayraktar Y. Experience of a single center with congenital hepatic fibrosis: a review of the literature. World J Gastroenterol. 2010;16:683–690. doi: 10.3748/wjg.v16.i6.683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Zeitoun D, Brancatelli G, Colombat M, Vilgrain V. Congenital hepatic fibrosis: CT findings in 18 adults. Radiology. 2004;231:109–116. doi: 10.1148/radiol.2311030108. [DOI] [PubMed] [Google Scholar]
  • 109.Akhan O, Karaosmanoglu AD, Ergen B. Imaging findings in congenital hepatic fibrosis. Eur J Radiol. 2007;61:18–24. doi: 10.1016/j.ejrad.2006.11.007. [DOI] [PubMed] [Google Scholar]
  • 110.Di Bisceglie AM, Befeler AS. Schiff's Diseases of the Liver. 10th ed. Lippincott Williams & Wilkins; PA: 2007. Cystic and nodular diseases on the liver; pp. 1231–1251. [Google Scholar]
  • 111.Kerr DN, Okonkwo S, Choa RG. Congenital hepatic fibrosis: the longterm prognosis. Gut. 1978;19:514–520. doi: 10.1136/gut.19.6.514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Stromeyer FW, Ishak KG. Nodular transformation (nodular “regenerative” hyperplasia) of the liver. A clinicopathologic study of 30 cases. Hum Pathol. 1981;12:60–71. doi: 10.1016/s0046-8177(81)80242-0. [DOI] [PubMed] [Google Scholar]
  • 113.Naber AH, Van Haelst U, Yap SH. Nodular regenerative hyperpla-sia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol. 1991;12:94–99. doi: 10.1016/0168-8278(91)90916-y. [DOI] [PubMed] [Google Scholar]
  • 114.Wanless IR. Micronodular transformation (NRH) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990;11:787–797. doi: 10.1002/hep.1840110512. [DOI] [PubMed] [Google Scholar]
  • 115.Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma and nodular regenerative hyperplasia; possible pathogenetic relationship. Am J Gastroenterol. 1996;91:879–884. [PubMed] [Google Scholar]
  • 116.Wanless IR, Godwin TA, Allen F, Feder A. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine (Baltimore) 1980;59:367–379. [PubMed] [Google Scholar]
  • 117.Qizilbash AH, Castelli M. Nodular regenerative hyperplasia of the liver: diagnosis by liver biopsy. Can MedAssocJ. 1980;122:1151–1154. [PMC free article] [PubMed] [Google Scholar]
  • 118.Kingham JGC, Levison DA, Stansfield AG, Dawson AM. Non-cirrhotic idiopathic portal hypertension: a long term follow up study. QJMed. 1981;199:259–268. [PubMed] [Google Scholar]
  • 119.Rougier P, Degott C, Rueff B, Benhamou JP. Nodular regenerative hyperplasia of the liver. Gastroenterology. 1978;75:169–172. [PubMed] [Google Scholar]
  • 120.Guarda LA, Hales MR. Nodular regenerative hyperplasia of the liver: report of two cases and review of the literature. J Clin Gastroenterol. 1981;3:157–164. doi: 10.1097/00004836-198106000-00010. [DOI] [PubMed] [Google Scholar]
  • 121.Ludwig J, Hashimoto E, McGill DB, van Heerden JA. Classification of hepatic venous outflow obstruction: ambiguous terminology of the Budd-Chiari syndrome. Mayo Clin Proc. 1990;65:51–55. doi: 10.1016/s0025-6196(12)62109-0. [DOI] [PubMed] [Google Scholar]
  • 122.DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease) Semin Liver Dis. 2002;22:27–42. doi: 10.1055/s-2002-23204. [DOI] [PubMed] [Google Scholar]
  • 123.Janssen HL, Meinardi JR, van Der Meer FJ. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96:2364–2368. [PubMed] [Google Scholar]
  • 124.Murad SD, Plessier A, Hernandez-Guerra M. Prospective follow-up study on 163 patients with Budd-Chiari syndrome: results from the European network for vascular disorders of the liver (EN-VIE) J Hepatol. 2007;46:S4. [Google Scholar]
  • 125.Dilawari JB, Bambery P, Chawla Y. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994;73:21–36. doi: 10.1097/00005792-199401000-00003. [DOI] [PubMed] [Google Scholar]
  • 126.Valla DC. Hepatic vein thrombosis (Budd-Chiari syndrome) Semin Liver Dis. 2002;22:5–14. doi: 10.1055/s-2002-23202. [DOI] [PubMed] [Google Scholar]
  • 127.Hadengue A, Poliquin M, Vilgrain V. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology. 1994;106:1042–1047. doi: 10.1016/0016-5085(94)90765-x. [DOI] [PubMed] [Google Scholar]
  • 128.Langlet P, Escolano S, Valla D. Clinicopathological forms and prognostic index in Budd-Chiari syndrome. J Hepatol. 2003;39:496–501. doi: 10.1016/s0168-8278(03)00323-4. [DOI] [PubMed] [Google Scholar]
  • 129.Gupta S, Barter S, Phillips GW, Gibson RN, Hodgson HJ. Comparison of ultrasonography, computed tomography and 99mTc liver scan in diagnosis of Budd-Chiari syndrome. Gut. 1987;28:242–247. doi: 10.1136/gut.28.3.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Hoekstra J, Janssen HL. Vascular liver disorders (I): diagnosis, treatment and prognosis of Budd-Chiari syndrome. Neth J Med. 2008;66:334–339. [PubMed] [Google Scholar]
  • 131.Ringe B, Lang H, Oldhafer KJ. Which is the best surgery for Budd-Chiari syndrome: venous decompression or liver transplantation? A single-center experience with 50 patients. Hepatology. 1995;21:1337–1344. [PubMed] [Google Scholar]
  • 132.Raju GS, Felver M, Olin JW, Satti SD. Thrombolysis for acute Budd-Chiari syndrome: case report and literature review. Am J Gastroenterol. 1996;91:1262–1263. [PubMed] [Google Scholar]
  • 133.Bilbao Jl, Pueyo JC, Longo JM. Interventional therapeutic techniques in Budd-Chiari syndrome. Cardiovasc Intervent Radiol. 1997;20:112–119. doi: 10.1007/s002709900117. [DOI] [PubMed] [Google Scholar]
  • 134.Molmenti EP, Segev DL, Arepally A. The utility of TIPS in the management of Budd-Chiari syndrome. Ann Surg. 2005;241:978–981. doi: 10.1097/01.sla.0000164180.77824.12. [Discussion 982-3.] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Richardson P, Guinan E. The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol. 1999;107:485–493. doi: 10.1046/j.1365-2141.1999.01680.x. [DOI] [PubMed] [Google Scholar]
  • 136.Bras G, Jaliffe DB, Stuart KL. Veno-occlusive disease of the liver with non-portal type of cirrhosis occurring in Jamaica. Arch Pathol. 1954;87:285–300. [PubMed] [Google Scholar]
  • 137.Carreras E, Bertz H, Arcese W. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. Blood. 1998;92:3599–3604. [PubMed] [Google Scholar]
  • 138.Sebagh M, Debette M, Samuel D. “Silent” presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. Hepatology. 1999;30:1144–1150. doi: 10.1002/hep.510300514. [DOI] [PubMed] [Google Scholar]
  • 139.Jones RJ, Lee KS, Beschorner WE. Veno-occlusive disease of the liverfollowingbone marrowtransplantation. Transplantation. 1987;44:778–783. [Google Scholar]
  • 140.Senzolo M, Germani G, Cholongitas E, Burra P, Burroughs AK. Veno-occlusive disease: update on clinical management. World J Gastroenterol. 2007;13:3918–3924. doi: 10.3748/wjg.v13.i29.3918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141.Toh HC, McAfee SL, Sackstein R, Cox BF, Colby C, Spitzer TR. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant. 1999;24:891–895. doi: 10.1038/sj.bmt.1701994. [DOI] [PubMed] [Google Scholar]
  • 142.Ben-Ari Z. Ascites after transplantation-a mystery. Liver Transpl. 2004;10:1221. doi: 10.1002/lt.20221. [DOI] [PubMed] [Google Scholar]
  • 143.Petaja J, Pitkanen S, Vettenranta K, Fasth A, Heikinheimo M. Serum tumor marker CA 125 is an early and sensitive indicator of veno-occlusive disease in children undergoing bone marrow transplantation. Clin Cancer Res. 2000;6:531–535. [PubMed] [Google Scholar]
  • 144.Helmy A. Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther. 2006;23:11–25. doi: 10.1111/j.1365-2036.2006.02742.x. [DOI] [PubMed] [Google Scholar]
  • 145.Lassau N, Auperin A, Leclere J, Bennaceur A, Valteau-Couanet D, Hartmann O. Prognostic value of Doppler-ultrasonography in hepatic veno-occlusive disease. Transplantation. 2002;74:60–66. doi: 10.1097/00007890-200207150-00011. [DOI] [PubMed] [Google Scholar]
  • 146.Shulman HM, Gooley T, Dudley MD. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation. 1995;59:1015–1022. doi: 10.1097/00007890-199504150-00017. [DOI] [PubMed] [Google Scholar]
  • 147.Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol. 1993;11:1729–1736. doi: 10.1200/JCO.1993.11.9.1729. [DOI] [PubMed] [Google Scholar]
  • 148.The WT, Beyer W, Pendleton JD. Genetic polymorphisms in glutathione S-transferase and plasminogen activator inhibitor and risk of veno-occlusive disease (VOD) Blood. 2000;96:390A. [Abstract]. [Google Scholar]

Articles from Journal of Clinical and Experimental Hepatology are provided here courtesy of Elsevier

RESOURCES